encyclopedia jump navigation jump search hepatitis hepatitis hepatitis change cell death body disease gastroenterology symptom skin appetite pain complication liver liver failure liver cancer duration term term cause viruse alcohol toxin autoimmune prevention vaccination hepatitis treatment liver transplant frequency case death year
hepatitis inflammation liver tissue people symptom discoloration skin white eye appetite vomit tiredness pain hepatitis term month hepatitis progress hepatitis result liver failure time form scare liver liver failure liver cancer
cause hepatitis viruse cause alcohol use medication toxin infection autoimmune disease steato hepatitis type hepatitis type hepatitis food water hepatitis b mother baby pregnancy childbirth hepatitis b c blood needle share drug user hepatitis d people hepatitis b
hepatitis immunization case hepatitis treatment lifestyle activity diet weight loss hepatitis medication system liver transplant option case
hepatitis people hepatitis people hepatitis people united states nash people hepatitis people hepatitis result death year liver scare liver cancer united states hepatitis people year result death word hpar
mean liver -itis
mean inflammation content
sign symptom hepatitis hepatitis hepatitis cause hepatitis mechanism hepatitis hepatitis diagnosis hepatitis alcoholic screen hepatitis prevention vaccine change treatment hepatitis hepatitis hepatitis hepatitis hepatitis alcoholic hepatitis recommendation hepatitis hepatitis epidemiology hepatitis hepatitis hepatitis history thought state school experiment australia antigen society culture burden case research direction hepatitis hepatitis population hiv pregnancy reference link
sign symptom eye
hepatitis spectrum presentation range lack symptom liver failure form hepatitis infection symptom hepatitis sign symptom liver dysfunction inflammation damage organ hepatitis
hepatitis phase
prodromal phase symptom symptom infection
fatigue nausea appetite pain headache fever present case hepatitis phase people symptom urine clay-color stool skin white eye prodrome week week symptom prodromal time people liver pain discomfort people spleen people weight loss recovery phase resolution symptom hepatitis elevation liver lab value liver case hepatitis resolve month hepatitis b case month
case hepatitis c
hepatitis autoimmune hepatitis hepatitis variation symptom cause case hepatitis sign reaction fever inflammation membrane organ eosinophil type blood cell suppression bone marrow activity hepatitis
hepatitis cell death complication hepatitis case hepatitis b d e addition autoimmune hepatitis complication instance hepatitis b d co-infection rate women hepatitis e rate case addition sign hepatitis people sign coagulopathy coagulation study encephalopathy confusion disorientation sleepiness mortality hepatitis result complication sepsis failure kidney failure hepatitis
case hepatitis period
hepatitis month hepatitis hepatitis course liver laboratory study screen purpose symptom inflammation patient symptom hepatitis fatigue nausea appetite pain disease process sign disease hepatitis function liver acne hair growth lack period women damage scare liver time cirrhosis condition liver ability function result jaundice weight loss coagulopathy ascite fluid collection edema leg swell complication encephalopathy varice syndrome liver cancer cause
cause hepatitis category ischemic autoimmune
agent viruse bacteria parasite
drug alcohol liver disease cause liver injury inflammation
cause hepatitis predisposition population
hepatitis article hepatitis
hepatitis type hepatitis hepatitis viruse hepatitis hepatitis hepatitis route country illness hepatitis
hepatitis b hepatitis c hepatitis d blood mucous membrane blood body fluid semen secretion particle saliva breastmilk
share utensil breastfeed transmission fluid sore cut
hepatitis b c hepatitis d virus hepatitis b hepatitis b adult hepatitis b infection progress state cirrhosis liver cancer infection infant children infection
hepatitis b case hepatitis c lead infection hepatitis c second cause cirrhosis second hepatitis blood transfusion factor spread hepatitis c virus screen blood product hepatitis c risk hepatitis c blood transfusion hepatitis granulosus
liver response symptom hepatitis serum hepatitis infection protozoan specy plasmodium specy liver inflammation protozoan cause hepatitis liver abscess
worm echinococcus dog tapeworm liver form characteristic hydatid cyst liver fluke hepatica clonorchis bile duct cause hepatitis liver fibrosis hepatitis
infection liver result liver abscess hepatitis liver disease abscess bacteria escherichia coly klebsiella bacteria time hepatitis meningitidis bartonella salmonella specy specy specy hepatitis infection mycobacteria specy coxiella specy hepatitis article hepatitis
alcohol consumption cause hepatitis cause cirrhosis hepatitis spectrum liver disease
range order severity reversibility steatosis hepatitis cirrhosis liver cancer hepatitis exposure alcohol alcoholics risk factor development hepatitis quantity duration alcohol intake alcohol intake excess gram alcohol day men gram day women development alcoholic hepatitis beer ounce wine 12g alcohol hepatitis liver symptom hepatitis liver failure hepatitis
agent medication toxin supplement hepatitis spectrum liver injury hepatitis hepatitis liver failure medication liver injury variety mechanism cell damage disruption cell metabolism change drug paracetamol exhibit dose-dependent liver damage cause reaction individual variation mechanism liver injury latency period exposure development illness
type drug liver injury analgesic paracetamol antibiotics amoxicillin-clavulanate valproate cholesterol-lower steroid contraceptive steroid anti-retroviral therapy treatment hivaid amoxicillin-clavulanate cause liver injury paracetamol toxicity cause liver failure united states europe
remedy supplement cause hepatitis cause hepatitis korea drug liver injury network case hepatotoxicity supplement united states supplement drug food drug administration institute health database consumer prescription non-prescription compound liver injury
exposure hepatotoxin ingestion inhalation skin absorption
toxin carbon tetrachloride mushroom phalloide liver disease article liver disease
hepatitis spectrum liver disease severity reversibility liver disease steato hepatitis nash cirrhosis liver cancer spectrum liver disease
liver disease people history alcohol use syndrome obesity insulin resistance diabete hypertriglyceridemia time liver disease steato hepatitis liver cell death liver inflammation fibrosis factor progression nafld nash obesity age ethnicity female gender diabete mellitus hypertension alt ast level ratio platelet count ultrasound score
stage nafld patient quadrant pain diagnosis basis liver function test disease symptom hepatitis image liver liver biopsy inflammation fibrosis characteristic patient nash cirrhosis nash cause liver disease united states article hepatitis
hepatitis disease response liver cell disease predisposition leukocyte antigen response autoimmune disease auto-antibody diagnosis patient autoimmune hepatitis antibody muscle antibody antineutrophil antibody autoantibody autoimmune hepatitis antibody liver kidney liver antigen sla hepatitis drug hydralazine methyldopa liver transplant viruse hepatitis virus measle
hepatitis spectrum hepatitis liver failure patient 2534 time diagnosis basis liver function test case sign symptom hepatitis autoimmune disease autoimmune hepatitis women patient sex age patient sign symptom fatigue anorexia acne arthritis pleurisy colitis rash hepatitis risk cirrhosis risk liver cancer year disease
people autoimmune hepatitis autoimmune disease hepatitis autoimmune disease liver cirrhosis cholangitis
disease scare fibrosis cirrhosis liver
cause hepatitis deficiency wilsons disease deficiency mutation gene result accumulation protein liver cell liver disease wilsons disease disease storage mineral amount iron body site liver cirrhosis wilsons disease excess amount copper liver brain cirrhosis dementia
liver deficiency wilsons disease hepatitis period childhood adulthood onset disease age hepatitis article hepatitis
hepatitis shock liver result blood flow liver shock heart failure insufficiency condition heart failure shock sepsis
blood test person hepatitis level transaminase enzyme ast alt
condition cause
hepatitis liver damage article hepatitis
hepatitis neonate variety cause adult infection hepatitis viruse toxoplasma rubella cytomegalovirus syphilis hepatitis abnormality cyst liver injury hepatitis disease glycogen storage disorder storage disorder hepatitis case biopsy multinucleate cell liver tissue disease cell hepatitis infection autoimmune disorder drug toxicity mechanism
mechanism cause hepatitis
insult liver injury activation response fibrosis cirrhosis hepatitis stage liver disease
pathway viruse hepatitis case hepatitis b c viruse apoptosis cell death infection liver cell arm system response damage death strength response type cell ability virus defense infection clearance disease persistence disease virus presence virus liver cell result wave inflammation injury wound heal time lead scare fibrosis carcinoma individual response risk infection killer cell driver response cytokine environment result recruitment t-cell type cytokine response hepatitis b c killer cell function hepatitis
hepatitis liver disease culmination cascade event injury
case steato hepatitis cascade change metabolism obesity insulin resistance dysregulation hepatitis excess alcohol use culprit event progression event accumulation acid breakdown product liver cell process process hepatocyte ability homeostasis effect molecule set stress response time deposition system receptor production cytokine tnf cause liver cell injury death event transition hepatitis set injury fibrosis set event cirrhosis carcinoma change hepatocyte evidence injury cell death apoptosis necrosis evidence inflammation zone liver variable degree fibrosis body diagnosis aminotransferase cause alt hepatitis b c d liver disease hepatitis autoimmune hepatitis wilsons disease deficiency ischemic hepatitis elevation ast liver disease
diagnosis hepatitis basis patient sign symptom history substance use history blood test image liver biopsy general hepatitis cause hepatitis patient blood test picture diagnosis cause hepatitis cause blood test case liver biopsy gold standard diagnosis analysis extent pattern inflammation fibrosis liver biopsy test risk bleed patient liver injury cirrhosis
blood test liver enzyme autoantibody acid test hepatitis virus blood chemistry blood count characteristic pattern liver enzyme abnormality cause stage hepatitis ast alt case hepatitis patient symptom degree elevation level predominance ast
alt elevation ratio ast alt diagnosis
ultrasound ct mry change liver tissue nodularity liver surface cirrhosis ct mry level detail visualization structure vessel tumor liver steatosis cirrhosis image test liver inflammation hepatitis fibrosis liver biopsy test inflammation fibrosis liver hepatitis article hepatitis
hepatitis blood test level antigen hepatitis surface core antigen antibody anti- hepatitis b surface antibody anti- hepatitis antibody dnarna infection week igm antibody blood infection recovery igg antibody body year patient igg antibody igm antibody virus infection recovery vaccination
case hepatitis b blood test virus antigen component particle antibody combination antigen antibody positivity information stage infection degree replication infectivity virus
factor steato hepatitis ash nonalcoholic steato hepatitis nash history alcohol use abuse patient alcohol use diagnosis hepatitis
alcohol diagnosis hepatitis obesity diabete syndrome
case alcoholic hepatitis pattern liver enzyme abnormality steato hepatitis astalt ratio steato hepatitis altast ratio
note liver biopsy find patient ash nash presence infiltration hepatocyte necrosis apoptosis form degeneration mallory body fibrosis vein sinuse hepatitis
purpose screen hepatitis people disease treatment disease progression transmission hepatitis
hepatitis cause illness liver disease
role screen status people risk virus people liver disease hepatitis infection liver failure people group hepatitis vaccine
risk need screen
people habit wash hand restroom diaper people access water people contact contact hepatitis drug user people liver disease people area hepatitis
presence anti- hepatitis igg blood infection virus vaccination hepatitis b
cdc routine hepatitis b screen population population people
country prevalence hepatitis
population state parent country prevalence hepatitis
population hiv drug user men sex men contact sex people hepatitis begine therapy liver enzyme cause blood organ tissue donor
screen blood test hepatitis b surface antigen hbsag
hbsag second test blood sample antibody hepatitis core antigen infection people blood test hbsag hepatitis b vaccine infection hepatitis c
cdc aasld acog screen people risk hepatitis c infection population people
drug user past drug user men sex men past hemodialysis recipient tattoo set recipient blood product organ united states adult state 1945-1965 mother worker healthcare set injury blood organ donor sex worker
people group exposure screen research screen interval aasld screen men sex men people 1945-1965 exposure risk
screen blood test hepatitis c virus antibody
hepatitis c virus antibody test rna disease prevention vaccine immunization schedule united states age year 2016 hepatitis article hepatitis vaccine
cdc hepatitis vaccine children age risk disease
children month age vaccination shot muscle dose month age month dose adult type vaccine
vaccine hepatitis dose month manufacturer vaccine hepatitis hepatitis b dose hepatitis b article hepatitis b vaccine
cdc routine vaccination children age hepatitis vaccine risk
routine vaccination hepatitis b dose shot muscle hospital
dose child month
baby mother hepatitis b surface antigen positivity dose addition vaccine hepatitis globulin hour birth
newborn infection year life
combination formulation hepatitis b vaccine
vaccine united states hepatitis c e change hepatitis
hepatitis route mainstay prevention vaccination hygiene access water handle sewage hepatitis b c
hepatitis b c blood fluid prevention screen blood transfusion use injection drug needle sharp practice healthcare set sex practice hepatitis d
hepatitis d virus person hepatitis virus prevention effort spread hepatitis b
people hepatitis infection risk superinfection hepatitis d virus strategy hepatitis hepatitis
hepatitis e route blood mother fetus
mainstay hepatitis e prevention hepatitis hygiene water practice hepatitis
alcohol consumption hepatitis cirrhosis recommendation alcohol consumption
drink day
drink week men
drink day
drink week
united states immunization decrease hospital admission expense hepatitis hepatitis
united states case hepatitis b group decrease children adolescent implementation guideline hepatitis c
hepatitis c infection year data decline needle exchange programme hepatitis
people hepatitis symptom number people disease estimate program alcoholics death cirrhosis success incidence hepatitis treatment
treatment hepatitis form severity disease cause
hepatitis article hepatitis
hepatitis state hospitalization treatment measure hydration nutrition
people hepatitis virus liver failure failure liver disease hepatitis c mortality risk factor age hepatitis case therapy liver transplant hepatitis article hepatitis
patient effect treatment age comorbid condition illness
patient warrant hospitalization sign ascite encephalopathy laboratory sign prothrombin time serum albumin serum bilirubin
case patient therapy case hepatitis analogue
dearth trial data drug treat resistance expert treatment case
hepatitis management replication progression disease drug treatment date united states
interferon alpha therapy hepatitis b side effect removal therapy treatment indication interferon polyethylene glycol interferon nucleoside analogue interferon peg ifn week injection interferon resistance antiviral monitor peg ifn cost 18000 year united states medication treatment duration week antiviral treatment patient minimum year peg ifn patient level activity patient cirrhosis nucleoside analogue lamivudine treatment world treatment area agent course treatment minimum year minimum month consolidation therapy
response therapy patient therapy response patient consolidation therapy year patient reactivation treatment lamivudine patient resistance treatment duration antiviral treatment patient hiv resistance part regimen nucleotide analogue patient resistance therapy entecavir resistance hepatitis treatment choice patient monotherapy patient hiv telbivudine treatment entecavir resistance tenofovir nucleotide analogue drug hiv infection patient treatment resistance
treatment peg ifn subject patient physician preference treatment initiation recommendation association study liver disease association study liver level status alt level case family history hcc liver biopsy patient cirrhosis treatment hbeag status alt level recommendation hbv dna level dna level iuml hbv dna level level patient cirrhosis treatment evaluation liver transplantation case hbv dna treatment treatment hbv term treatment entecavir tenofovir hepatitis c article hepatitis c
contrast hepatitis b progression hepatitis c goal hepatitis c treatment prevention carcinoma way risk hcc response svr svr load week treatment completion cure treatment drug act interferon peg ifn ribavirin combination basis therapy duration response treatment genotype agent area country agent agent target protein replication class
protease inhibitor boceprevir inhibitor daclatasvir polymerase inhibitor dasabuvir
drug combination ribavirin patient genotype genotype gt1 genotype united states world act regimen therapy gt1 combination sofosbuvir sofldv week patient fibrosis cirrhosis patient disease need week treatment fibrosis cirrhosis treatment week cost factor access drug nation cost gt1 regimen
association study liver disease disease society america treatment patient hepatitis c infection condition life expectancy hepatitis d article hepatitis d
hepatitis d treatment
alpha activity basis hepatitis e article hepatitis e
hepatitis treatment hepatitis e rest nutrition hydration hospitalization case women hepatitis
treatment hepatitis treatment alcoholism alcohol reversal liver disease life patient disease stage benefit prevention liver injury addition referral psychotherapy treatment program treatment evaluation treatment patient sign symptom ascite encephalopathy infection
hepatitis prognosis treatment patient month evidence treatment life month mortality treatment option ptx tnf inhibitor corticosteroid prednisone prednisolone cs corticosteroid n-acetylcysteine cs nac corticosteroid pentoxifylline cs data cs cs nac mortality corticosteroid patient infection kidney failure pancreatitis case case case basis lieu cs evidence treatment cs data evidence benefit placebo drug treatment patient risk term month
evidence milk thistle extract survival liver disease liver test serum bilirubin ggt side effect recommendation milk thistle study recommendation
people hepatitis bed rest activity diet people nausea food day bulk intake part day phase disease feed patient food intake nausea vomit
people hepatitis drug liver treatment option hepatitis harm development hepatitis
precaution isolation isolation case incontinence hepatitis e bleed hepatitis b c hepatitis
patient hepatitis infection complication infection
hepatitis infection course recovery 9599 patient factor outcome condition present symptom ascite encephalopathy mortality rate hepatitis total case hepatitis rate population infection hepatitis b d women
contrast hepatitis hepatitis risk hepatitis cirrhosis patient hepatitis c
complication hepatitis pancreatitis neuropathy hepatitis
course case hepatitis hepatitis complication
hepatitis hepatitis
case hepatitis e hepatitis women case mortality rate case hepatitis rise patient recovery
liver transplantation patient liver failure
hepatitis d infection case hepatitis b hepatitis phenomenon hepatitis
hepatitis infection progress form age patient increase rate progression case infant risk adult survival rate hepatitis range case case cirrhosis
patient hepatitis d time hepatitis b infection people hepatitis b hepatitis d infection 80-90 liver disease progression
hepatitis c cirrhosis estimate cirrhosis prevalence year infection cause mortality hepatitis c end stage liver disease carcinoma term complication cause death hepatitis
rate mortality increase progression liver disease
series patient cirrhosis hcv survival rate survival rate drop cirrhosis
epidemiology hepatitis hepatitis
hepatitis world outbreak epidemics contamination water food source hepatitis infection children age infection infant children illness contrast adult infection rate resource country sanitation population region children year rate disease outbreak availability childhood vaccine infection united states incidence rate infection adult adult illness population risk region men sex men exposure primate individual clote disorder clote factor individual history liver disease hepatitis hepatitis drug user hepatitis article hepatitis b
hepatitis b cause hepatitis world carrier virus united states patient hepatitis b infection exposure lifetime carrier virus risk infection drug user individual behavior healthcare worker individual history transfusion organ transplant patient dialysis patient newborn process death world hepatitis b region africa east asia adult carrier carrier rate nation population region transmission exposure birth contact infant hepatitis c article hepatitis c
hepatitis c cause liver cirrhosis carcinoma reason liver transplantation complication people world disease world population region africa asia south america prevalence population egypt rate hepatitis c infection contamination schistosomiasis treatment 1950s1980 united states adult hepatitis c people 19451965 group people prevalence population carrier hepatitis c infection status mode transmission hepatitis c virus exposure blood product blood transfusion drug injection history drug injection risk factor hepatitis c population individual behavior infant mother healthcare worker hepatitis d article hepatitis d
hepatitis d virus hepatitis context co-infection hepatitis virus contact needle hepatitis d region united states northern europe population risk drug user individual transfusion hepatitis hepatitis b virus co-infect individual hepatitis article hepatitis e
hepatitis hepatitis e outbreak epidemics contamination water source death people virus adult hepatitis women hepatitis e infection hepatitis trimester mortality rate individual system organ transplant recipient infection united states rate world africa asia america east genotype world evidence hepatitis e infection animal reservoir infection hepatitis
hepatitis form mortality people men women risk complication secondary body fat difference alcohol metabolism factor age binge pattern status obesity hepatitis c people hepatitis c population presence hepatitis c virus disease progression cirrhosis carcinoma mortality obesity likelihood progression cirrhosis individual alcoholic hepatitis proportion individual progress cirrhosis hepatitis
steato hepatitis nash reason liver transplantation united states year supplant liver disease hepatitis c population prevalence nash world patient cirrhosis year progress carcinoma prevalence carcinoma nafld nash cause cirrhosis patient united states population history hepatitis thought
account syndrome hepatitis
clay tablet handbook sumerian observation jaundice
sumerian liver home soul find jaundice attack liver devil bc hippocrates documentation epidemic jaundice course cohort patient week
bile liver phlegm blood eruptsafter eruption patient talk nonsense bark dog
condition war jaundice role cause mortality troop war war world war world war estimate soldier hepatitis
soldier vaccine disease fever vaccine serum epidemics hepatitis researcher england findlay maccallum epidemics agent fever virus case jaundice month vaccination 3100 patient
seed virus strain case jaundice vaccination state school experiment
new york university researcher saul krugman research experiment children state school new york facility hepatitis infection student body
student gamma type antibody
protection infection antibody hepatitis virus student
student milkshake children
research controversy people ethics target population
henry beecher critics article new england journal medicine parent risk consent research benefit expense children family children research project admission school support resource community support research term benefit understand hepatitis virus willowbrook example debate ethics australia antigen
leap research dr
researcher nih research hepatitis lipoprotein genetics
globe collect blood sample interplay disease environment genetics goal intervention individual interaction blood patient hemophilia transfusion protein blood aborigine protein australia antigen focus research
prevalence protein blood patient country association antigen disease leukemia syndrome conclusion australia antigen hepatitis
david dane hepatitis b londons middlesex hospital virion dane particle association surface hepatitis b virus australia antigen hepatitis surface antigen hbsag
antigen hepatitis b vaccine plasma hbsag nobel prize medicine
citation society culture burden
hepatitis account portion healthcare expenditure nation rise country hepatitis infection event cost united states cost case average work day adult report hospitalization hepatitis cost average 6900 healthcare cost effectiveness study vaccination adult combination hepatitis b vaccination children risk group people area healthcare worker
hepatitis b account percentage health care spend region asia south koreas health care expenditure cost majority sum disease symptom complication hepatitis infection united states hospitalization cost year number introduction drug therapy vaccination campaign
people hepatitis c user health care system person hepatitis c united states cost number people cirrhosis cost people cirrhosis time effect hepatitis cost study cost united states canada cost cirrhosis expenditure virus peak cad396 year case
outbreak hepatitis virus united states history people food restaurant monaca pennsylvania people restaurant september october virus result outbreak attention health official emergency medicine physician increase case hepatitis county investigation cdc source outbreak use onion
restaurant onion stock farm mexico time onion use water crop irrigation rinse ice handle vegetable individual onion outbreak hepatitis state magnitude cdc restaurant use bucket onion plant number vector infection outbreak restaurant source people hepatitis globulin restaurant contact research direction hepatitis b
paper mouse model hepatitis infection protein clearance virus implication disease
hepatitis e
march group china article development vaccine hepatitis e march united states government process recruit participant phase trial drug population hiv co-infection
person hiv burden co-infection study likelihood hepatitis c virus time individual hiv prevalence hiv-hcv people drug use risk factor infection study prevalence co-infection 824 drug population study co-infection hiv men sex men msm prevalence anti- hepatitis c antibody hiv msm drug pregnancy hepatitis b
transmission contributor hbv case year 3550 transmission mother neonate country transmission neonate exposure blood secretion birth risk progression infection adult virus neonate subject transmission risk transmission blood hbsag hbeag
risk transmission cdc screen women hbv visit women hbv vaccine evidence association study liver disease therapy women load body evidence therapy trimester transmission neonate review pregnancy registry database risk anomaly tenofovir reason potency risk resistance aasld drug review meta-analysis trimester transmission hbv effect
state evidence mode delivery cesarean transmission mother hbv
cdc neonate mother hbv hepatitis globulin hbv vaccine hour birth infant hbv vaccine breastfeed hepatitis c
estimate rate transmission range review meta-analysis risk women study risk transmission women study risk transmission women risk transmission virus mother blood
evidence mode delivery cesarean effect transmission
women breastfeed cdc guideline breastfeed nipple risk transmission hepatitis e
women contract risk hepatitis mortality rate trimester review meta-analysis study people case-fatality rate cfr women failure
